Holen Sie sich die Stockscreener-App
6.39
6.50%
0.39
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
BTIG Research Raises Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $9.00 - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.6%What's Next? - MarketBeat
Are Medical Stocks Lagging BellRing Brands (BRBR) This Year? - Yahoo Finance
Charles Schwab Investment Management Inc. Purchases 10,262 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
ADPT stock touches 52-week high at $6.71 amid robust gains By Investing.com - Investing.com South Africa
ADPT stock touches 52-week high at $6.71 amid robust gains - Investing.com
Jacobs Levy Equity Management Inc. Makes New $736,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Point72 Asset Management L.P. Makes New $2.54 Million Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Pier Capital LLC Grows Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions - Yahoo Finance
ADPT (Adaptive Biotechnologies) 10-Year Sortino Ratio : N/A (As of Dec. 06, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) 1-Year Sortino Ratio : 1.18 (As of Dec. 06, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies Corp (ADPT) With A Potential Upside Of More Than -193.16% - Stocks Register
Adaptive Biotechnologies (STU:1HM) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com
Matrix Capital Management Company LP Sells 10,922,590 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (FRA:1HM) Earnings Yield (Joel Gre - GuruFocus.com
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting - Yahoo Finance
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Short Interest Down 8.5% in November - MarketBeat
Adaptive Biotechnologies (STU:1HM) Operating Margin % : -70.27% (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies (STU:1HM) EPS (Diluted) : €-1.23 (TTM As of Sep. 2024) - GuruFocus.com
Cerity Partners LLC Boosts Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Rubric Capital Management LP Raises Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Massachusetts Financial Services Co. MA Lowers Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? - Benzinga
Millrace Asset Group Inc. Takes $1.40 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (FRA:1HM) Operating Margin % : -70.27% (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals (NASDAQ:TARS) versus Adaptive Biotechnologies (NASDAQ:ADPT) Financial Survey - Defense World
Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares - Investing.com India
Head to Head Comparison: Adaptive Biotechnologies (NASDAQ:ADPT) and Ginkgo Bioworks (NYSE:DNA) - Defense World
Adaptive Biotechnologies Corp: Is ADPT Stock Worth Buying? - Stocks Register
Short Interest in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Declines By 5.5% - Defense World
William Blair Has Bullish Forecast for ADPT FY2024 Earnings - MarketBeat
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Decrease in Short Interest - MarketBeat
Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know - Yahoo Finance
Rubric Capital Management LP's Strategic Acquisition in Adaptive Biotechnologies Corp - GuruFocus.com
Matrix Capital Management Reduces Stake in Adaptive Biotechnologies Corp - GuruFocus.com
Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 12.7% Following Analyst Upgrade - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Trading 12.7% Higher After Analyst Upgrade - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $7.00 - MarketBeat
ADPT (Adaptive Biotechnologies) Cash From Other Investing A - GuruFocus.com
Adaptive Biotechnologies Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nikko Asset Management Americas, Inc. Expands Stake in Adaptive Biotechnologies Corp - GuruFocus.com
Earnings call: Adaptive Biotechnologies posts robust MRD revenue growth - Investing.com
ARK Investment Management LLC Buys 189,134 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highl - GuruFocus.com
Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highlights: Strong MRD Growth Amidst ... - Yahoo Finance
ADPT stock touches 52-week high at $5.81 amid biotech rally By Investing.com - Investing.com South Africa
ADPT stock touches 52-week high at $5.81 amid biotech rally - Investing.com Canada
Adaptive Biotechnologies earnings beat by $0.07, revenue topped estimates - Investing.com
Adaptive Biotechnologies : Q3 2024 Earnings Presentation - Marketscreener.com
Adaptive Biotechnologies: Q3 Earnings Snapshot - CT Insider
ADPTAdaptive Biotechnologies Corporation Latest Stock News & Market Updates - StockTitan
Adaptive Biotechnologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):